丹蛭降糖胶囊联合达格列净治疗2型糖尿病周围血管病变的临床研究  

Clinical study on the combination of the Danzhi Jiangtang Capsule and dapagliflozin for type 2 diabetes mellitus with peripheral vascular disease

作　　者：刘剑[1] 方朝晖[1] #倪英群[1] 赵进东[1] 陆瑞敏[1] 王奔 严瑜珊 LIU Jian;FANG Zhaohui;NI Yingqun;ZHAO Jindong;LU Ruimin;WANG Ben;YAN Yushan(Department of Endocrinology,The First Affiliated Hospital of Anhui University of Chinese Medicine,Hefei 230031,China;The First Clinical Medical School of Anhui University of Chinese Medicine,Hefei 230038,China)

机构地区：[1]安徽中医药大学第一附属医院内分泌科,合肥230031 [2]安徽中医药大学第一临床医学院

出　　处：《北京中医药大学学报》2024年第8期1119-1125,共7页Journal of Beijing University of Traditional Chinese Medicine

基　　金：国家自然科学基金项目(No.81774286,No.82274468);国家中医药管理局中医科技与创新能力提升项目;安徽省高校协同创新项目(No.GXXT-2020-025)。

摘　　要：目的探讨丹蛭降糖胶囊联合达格列净对2型糖尿病周围血管病变患者的血脂谱及相关炎性指标的影响。方法将2021年4月—2023年4月就诊于安徽中医药大学第一附属医院内分泌科且符合纳入标准的2型糖尿病周围血管病变的72例患者采用随机数字表法分为试验组和对照组,每组36例。对照组患者在常规治疗的基础上加用达格列净,试验组患者在对照组基础上予丹蛭降糖胶囊,连续12周。观察2组患者治疗前后糖脂代谢相关指标、超敏C反应蛋白(hs-CRP)、身体质量指数(BMI)、中医证候积分变化情况,以及临床疗效。结果治疗后,与对照组比较,试验组患者空腹血糖(FPG)、餐后2 h血糖(2 hPG)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、hs-CRP、BMI均降低,高密度脂蛋白胆固醇(HDL-C)升高,中医证候总积分及各单项分数均下降,临床疗效更好(均P<0.05)。与治疗前比较,治疗后2组患者FPG、2 hPG、TG、TC、LDL-C、hs-CRP均降低,HDL-C均升高,中医证候总积分下降(均P<0.05)。结论丹蛭降糖胶囊联合达格列净治疗2型糖尿病周围血管病变,可调节血脂谱、降低炎性因子、改善患者症状,中西医结合治疗更有利于控制病情,作为一种联合治疗方法可在临床推广使用。Objective This study aimed to explore the effect of the combined Danzhi Jiangtang Capsule with dapagliflozin on the blood lipid profile and related inflammatory markers in patients with type 2 diabetes mellitus with peripheral vascular disease.Methods 72 patients with type 2 diabetes mellitus with peripheral vascular disease who met the inclusion criteria were admitted to the Department of Endocrinology,The First Affiliated Hospital of Anhui University of Chinese Medicine,from April 2021 to April 2023.The patients were assigned to the experimental group and the control group using the random number table method(36 cases in each group).The control group was treated with dapagliflozin in addition to standard treatment,while the experimental group received the Danzhi Jiangtang Capsule for 12 weeks.Clinical efficacy,glucose and lipid metabolism indicators,hypersensitive C-reactive protein(hs-CRP),body mass index(BMI)levels,and traditional Chinese medicine(TCM)syndrome scores were observed pre-and post-treatment.Results In post-treatment,the clinical efficacy was higher in the experimental group than in the control group.Significant reductions in fasting blood glucose(FPG),2 h postprandial glucose(2 hPG),triglycerides(TG),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),hs-CRP,BMI,and increased high-density lipoprotein cholesterol(HDL-C)were observed.Scores for TCM syndrome and individual items also decreased(P<0.05).Comparisons within the groups for pre-and post-treatment showed reductions in FPG,2 hPG,TG,TC,LDL-C,hs-CRP,and an increase in HDL-C,along with a decrease in total scores of TCM syndrome(P<0.05).Conclusion The Danzhi Jiangtang Capsule combined with dapagliflozin in the treatment of type 2 diabetes mellitus with peripheral vascular disease can regulate the blood lipid profile,reduce inflammatory factors,and improve patient′s symptoms.Integrated traditional Chinese and Western medicine treatment are more conducive to controlling the disease,and TCM can be used in clinical practice as a comb

关 键 词：糖尿病周围血管病变 丹蛭降糖胶囊 血脂谱 超敏C反应蛋白 中医证候 

分 类 号：R259[医药卫生—中西医结合]